{"Clinical Trial ID": "NCT00338286", "Intervention": ["INTERVENTION 1:", "- Care Standard (SOC)", "The participants received standard support care as a packaged red blood cell transfusion (RCC) in accordance with the investigator's discretion.", "INTERVENTION 2:", "Epoetin Alfa", "Participants received SOC plus epoetin alfa 40,000 international units (IU) subcutaneously (SC) once a week."], "Eligibility": ["Incorporation criteria:", "(e.g., tissue slide) breast cancer", "HER2/NEU positive or negative", "Clinical evidence of metastasis (e.g. biopsy) with at least 1 measurable metastatic lesion (M1) prior to the start of current chemotherapy", "Received 1st and 2nd line chemotherapy", "Hemoglobin (Hb) <= 11g/dL at randomization", "There are plans to receive at least 2 additional chemotherapy cycles", "Life expectancy > 6 months", "Note from the Eastern Cooperative Oncology Group 0 or 1", "At least 18 years of age using effective or surgically sterile or postmenopausal contraception for 1 year", "- Exclusion criteria:", "A second active cancer", "No recent history of clinically significant thrombovascular event", "Current treatment with anticoagulants", "A brain metastasis or CNS intervention", "- Secondary anaemia for another cause", "A recent use (in the previous 1 month) of an ESA", "Pregnant or lactating patient", "A progressive disease during adjuvant/neoadjuvant chemotherapy", "A metastatic disease that is rapidly progressive or life-threatening", "Concomitant endocrine treatment", "One patient with a local metastasis site and successfully treated surgically."], "Results": ["Performance measures:", "\u00b7 Progression Free Survival", "Participants who had not progressed and were still alive at the time of the clinical cut-off were censored during the last assessment of the disease prior to the clinical cut-off. With respect to the PD or death with a missing interval immediately prior to the event, progression-free survival (PFS) was censored during the last assessment of the disease prior to the missing interval. Participants who withdrew from the study (withdrawal of consent or loss of follow-up) without progression were censored at the time of the last assessment of the disease.", "Time limit: From date of randomization to date of disease progression (PD) or death, whichever occurs first (up to 8.4 years)", "Results 1:", "Name of Arm/Group: Standard of Care (SOC)", "Description of the arm and group: Participants received standard support care in the form of packaged red blood cell transfusion (RBC) at the discretion of the investigator.", "Total number of participants analysed: 1048", "Median (95% confidence interval)", "Unit of measurement: Month 7.4 (7.1 to 7.6)", "Results 2:", "Title of the arm/group: Epoetin Alfa", "Description of the arm/group: Participants received SOC plus epoetin alfa 40,000 international units (IU) subcutaneously (SC) once a week.", "Total number of participants analysed: 1050", "Median (95% confidence interval)", "Unit of measure: Month 7.4 (6.9 to 7.6)"], "Adverse Events": ["Undesirable Events 1:", "Total: 229/1045 (21.91 per cent)", "Agranulocytosis * 0/1045 (0.00 %)", "Anemia * 15/1045 (1.44%)", "* 0/1045 (0.00 %)", "Neutropenia * 29/1045 (2.78%)", "Leukopenia * 9/1045 (0.86%)", "Neutropenia * 55/1045 (5.26%)", "Neutrophilia * 1/1045 (0.10%)", "Pancytopenia * 3/1045 (0.29%)", "Thrombocytopenia * 12/1045 (1.15 %)", "Acute myocardial infarction * 2/1045 (0.19%)", "Adverse Events 2:", "Total: 251/1051 (23.88%)", "Agranulocytosis * 1/1051 (0.10%)", "Anemia * 10/1051 (0.95%)", "* 1/1051 (0.10%)", "Febrile Neutropenia * 40/1051 (3.81 %)", "Leukopenia * 10/1051 (0.95%)", "Neutropenia * 52/1051 (4.95%)", "Neutrophilia * 0/1051 (0.00 %)", "Pancytopenia * 7/1051 (0.67%)", "Thrombocytopenia * 18/1051 (1.71%)", "Acute myocardial infarction * 2/1051 (0.19%)"]}